protein

Recombinant Human Interferon-Omega (rHuIFN-omega)

MBS546319

0.02 mg

165 USD

Recombinant Protein

Recombinant Human Interferon-Omega (rHuIFN-omega)

[IFN-omega]

[IFN-omega 1, partial; Interferon omega-1; interferon omega-1; interferon, omega 1; Interferon alpha-II-1]

[IFNW1; IFNW1]

IFNW1_HUMAN

172

CDLPQNHGLL SRNTLVLLHQ MRRISPFLCL KDRRDFRFPQ EMVKGSQLQK AHVMSVLHEM LQQIFSLFHT ERSSAAWNMT LLDQLHTGLH QQLQHLETCL LQVVGEGESA GAISSPALTL RRYFQGIRVY LKEKKYSDCA WEVVRMEIMK SLFLSTNMQE RLRSKDRDLG SS

> 97 % by SDS-PAGE and HPLC analyses

Lyophilized from a 0.2um filtered concentrated solution in PBS, pH 7.4.

This lyophilized preparation is stable at 2-8°C, but should be kept at -20°C for long term storage, preferably dessicated. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -70°C. Avoid repeated freeze/thaw cycles.

Source: Escherichia coli. Biological Activity: Fully biologically active when compared to standard. The EDso as determined by a chemotaxis bioassay using human TF-l cells is less than 0.01 ng/ml,corresponding to a specific activity of > 1.0 x 10 8 IU/mg. Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder. Endotoxin: Less than 1 EU/ug of rHulFN-omega as determined by LAL method. Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at <= -20°c. Further dilutions should be made in appropriate buffered solutions.

Interferon-Omega (IFN-omega) coded by IFNWl gene in human, is a number of the type I interferon family, which includes IFN-alpha, IFN-beta, and IFN-omega. The IFNAR-1/IFNAR-2 receptor complex can help with the signal transduction, followed the antiviral or the antiproliferative actions. IFN-omega is derived from IFN-alpha/beta and share 75 % sequence with IFN-alpha. It has two intramolecular disulfide bonds which are crucial for activities. MireSluis et al have described bioassays for IFN-alpha, IFN-beta, and IFN-omega that exploit the ability of these factors to inhibit proliferation of TF-l cells induced by GM-CSF. The bioassays can be used also with Epo and TF-l cells, or Epo and Epo-transfected UT-7 cells.

55275060

AAV49320.1

Approximately 20.0 kDa, containing 172 amino acid residues with two conserved disulfide bonds

Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); Jak-STAT Signaling Pathway (83077); Jak-STAT Signaling Pathway (488); RIG-I-like Receptor Signaling Pathway (117292); RIG-I-like Receptor Signaling Pathway (116128)

The protein encoded by this gene is an interferon and possesses antiviral activity. The encoded protein binds to the interferon alpha/beta receptor but not to the interferon gamma receptor. This intronless gene has several pseudogenes spread throughout the genome. [provided by RefSeq, Nov 2015]

IFNW1: Belongs to the alpha/beta interferon family. Protein type: Secreted; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 9p22. Cellular Component: extracellular space. Molecular Function: cytokine activity; hematopoietin/interferon-class (D200-domain) cytokine receptor binding; interferon-alpha/beta receptor binding. Biological Process: adaptive immune response; B cell differentiation; B cell proliferation; cell cycle arrest; cytokine and chemokine mediated signaling pathway; defense response to virus; humoral immune response; innate immune response; natural killer cell activation during immune response; positive regulation of peptidyl-serine phosphorylation of STAT protein; response to exogenous dsRNA; response to virus; T cell activation during immune response

0.02 mg

165 USD

0.1 mg

220

1 mg

930